Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-05-31

Study Completion Date

2006-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out what effects, good or bad, that thalidomide and temodar have on patients with neuroendocrine tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma

NCT00098865

Central Nervous System Tumor, Pediatric Neuroblastoma

COMPLETED PHASE2

A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors

NCT00251797

Brain and Nervous System Cancer

COMPLETED PHASE1

Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00052416

Leukemia Lymphoma

COMPLETED PHASE1

Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers

NCT00003754

Unspecified Childhood Solid Tumor, Protocol Specific

COMPLETED PHASE2

An Open Protocol for the Compassionate Use of Thalidomide

NCT00081757

Multiple Myeloma

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Patients will receive thalidomide orally once daily continuously unless they experience significant side effects. Temodar is given orally once a day for one week, followed by a one week break period. This one week on/one week off schedule will continue for the duration of treatment unless there are significant side effects.
* After eight weeks (2 cycles) a CT scan will be performed to see how the treatment has affected the patient's tumor. Patients will continue taking the study drug unless there is evidence of tumor growth.
* Regular blood tests will be done weekly during the first two months to make sure that the treatment is not resulting in serious side effects. If there are no side effects during the first two months, the blood tests may decrease in frequency to every two weeks.
* Immediately after the patient has completed the study they will be evaluated by physical exam, blood work, and a CT scan. The follow-up will consist of clinic visits and phone calls every 3 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuroendocrine Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thalidomide

Intervention Type DRUG

Temodar

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed locally unresectable or metastatic neuroendocrine tumor excluding small cell carcinoma
* Prior treatment with chemoembolization or cryotherapy is allowed
* Radiotherapy is allowed if completed more than 4 weeks prior to study.
* Measurable disease as defined by RECIST criteria
* Age greater than or equal to 18 years.
* ECOG performance status of less than or equal to 2
* ANC \>1,500/mm3
* Platelet Count \> 100,000/mm3
* Hemoglobin \> 9 g/dl
* Serum creatinine \< 1.5 x ULN
* Total bilirubin \< 2 x ULN
* SGOT and SGPT \< 2 x ULN
* Alkaline phosphatase \< 2 x ULN
* Life expectancy of greater than 12 weeks

Exclusion Criteria

* Clinically symptomatic central nervous system metastases or carcinomatous meningitis
* Myocardial infarction in past 6 months
* Major surgery in past two weeks
* Uncontrolled serious medical or psychiatric illness
* Insufficient recovery from all active toxicities of prior therapies
* Active nonmalignant systemic disease
* Frequent vomiting or medical condition that could interfere with oral medication intake
* Known HIV positivity or AIDS-related illness
* Pregnant or nursing women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No